News | Stereotactic Body Radiation Therapy (SBRT) | April 06, 2018

First Patient Treated in Online Adaptive Radiotherapy Trial With CyberKnife System

New clinical trial evaluates use of online-adaptive stereotactic body radiation therapy approach in the treatment of oligometastases

First Patient Treated in Online Adaptive Radiotherapy Trial With CyberKnife System

April 6, 2018 — Accuray Inc. and Erasmus MC announced the first patient has been successfully treated using an online-adaptive (OA) approach together with the CyberKnife System. The patient, treated for oligometastases in the pelvic region, is part of a new clinical trial conducted at Erasmus MC, the largest university medical center in the Netherlands, evaluating OA stereotactic body radiation therapy (SBRT) delivered by the CyberKnife platform. The trial brings the hospital one step closer to its goal of providing individual, personalized medicine.

"At Erasmus MC our goal is to use innovative approaches to provide customized, effective treatments that help extend or improve the quality of life of people diagnosed with cancer, regardless of the stage of their cancer diagnosis," said J.J. Nuyttens, M.D., Ph.D., radiation oncologist, Department of Radiation Oncology, Erasmus MC. "We initiated this trial because we want to improve local cancer control and minimize toxicities in people with pelvic or intra-abdominal oligometastases."

Oligometastastic disease occurs when cancer cells from the primary tumor travel to other parts of the body and form a small number (less than six) of lesions. The cancerous cells are in an intermediate state; they are no longer confined to their initial location nor have they spread widely throughout the body. Radiation treatment of oligometastatic disease in the pelvic or intra-abdominal area is challenging because of the close proximity of healthy organs very sensitive to radiation. From one day to the next there can be a significant variation in the position of these organs, and it can be difficult to account for the changes in their location on a daily basis.

To address this issue, Accuray and Erasmus MC are partnering to develop an integrated, advanced imaging solution tailored for use with the CyberKnife System. The purpose is to enable clinicians to adapt the treatment plan to daily anatomical changes within the patient. According to Nuyttens, "this OA-SBRT strategy provided the treated patient with an optimal combination of dose to the tumor and sparing of the surrounding healthy organs."

This study is a non-randomized single arm phase II clinical trial evaluating the use of OA-SBRT for the treatment of oligometastatic disease in the pelvic or para-aortic region. In total, 53 patients will be enrolled and will be followed for three years. A prescription dose of 45 Gy will be delivered in five fractions by the CyberKnife System. The primary study objectives are to evaluate local control, survival and toxicity.

For more information: www.accuray.com

 

Related Content

VolparaDensity With Tyrer-Cuzick Model Improves Breast Cancer Risk Stratification
News | Breast Density | May 22, 2019
Research has demonstrated use of Volpara Solutions' VolparaDensity software in combination with the Tyrer-Cuzick Breast...
Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
Varian Acquiring Cancer Treatment Services International
News | Radiation Therapy | May 21, 2019
Varian Medical Systems announced it has entered into a definitive agreement to acquire India’s Cancer Treatment...
Videos | Radiation Therapy | May 21, 2019
This is a walk through of the ViewRay MRIdian MRI-guided radiotherapy system installed at ...
Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer
News | Radiation Therapy | May 20, 2019
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast...
AI Detects Unsuspected Lung Cancer in Radiology Reports, Augments Clinical Follow-up
News | Artificial Intelligence | May 20, 2019
Digital Reasoning announced results from its automated radiology report analytics research. In a series of experiments...
New Study Evaluates Head CT Examinations and Patient Complexity
News | Neuro Imaging | May 17, 2019
Computed tomography (CT) of the head uses special X-ray equipment to help assess head injuries, dizziness and other...
New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Managing Architectural Distortion on Mammography Based on MR Enhancement
News | Mammography | May 15, 2019
High negative predictive values (NPV) in mammography architectural distortion (AD) without ultrasonographic (US)...